MGTXHealthcare · BiotechnologyThe 8 Wall Street analysts covering MeiraGTx Holdings Plc hold a median 12-month price target of $24 — +147.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores MeiraGTx Holdings Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Accruals (12): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MGTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +147.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2026 | Goldman Sachs | Initiates | Neutral | $16 |
| 14 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 14 Aug 2026 | RBC Capital | Maintains | Outperform | $26 → $27 |
| 8 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 8 July 2026 | RBC Capital | Maintains | Outperform | — |
| 8 July 2026 | RBC Capital | Maintains | Outperform | $25 → $26 |
| 15 May 2026 | RBC Capital | Maintains | Outperform | — |
| 22 Apr 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Apr 2026 | RBC Capital | Maintains | Outperform | — |
| 1 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 27 Mar 2026 | B of A Securities | Maintains | Buy | — |
| 27 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 27 Mar 2026 | Piper Sandler | Maintains | Overweight | — |
| 24 Nov 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 14 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 14 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 11 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
| 21 Oct 2025 | Raymond James | Initiates | Strong Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MGTX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, MeiraGTx Holdings Plc returned +8.7% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 55% of US stocks
Cheaper than 48% of US stocks
Cheaper than 23% of US stocks
Cheaper than 54% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 82% of US stocks
Higher than 95% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MeiraGTx Holdings Plc has a market value of $911.4M and an enterprise value of $880.8M.
Revenue in the twelve months to 30 June 2026: $397.5M. The latest quarter grew 8608.6% year on year.
Net income over the same four quarters: $78.9M, a 19.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$14.2M.
Trailing P/E: 10.9×; forward P/E: −6.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MeiraGTx Holdings Plc employs 393 people — $1.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MeiraGTx Holdings Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MeiraGTx announced four posters for the ESGCT 2026 Annual Congress and the NEALS Annual Meeting, highlighting its genetic medicine and cell therapy platforms.
Why it matters — The presentations showcase the breadth of MeiraGTx’s platforms at two scientific meetings.
MeiraGTx Holdings plc announced the appointment of Alan M. Sebulsky, an accomplished healthcare portfolio manager, to its Board of Directors. The appointment was announced via a press release dated September 23, 2026, from London and New York.
Why it matters — Adding an experienced healthcare portfolio manager to the board brings financial and industry expertise that could support the company's strategic direction as a clinical-stage genetic medicines firm.
Graviton BioScience Corporation announced the publication in Signal Transduction and Targeted Therapy of positive Phase 1b trial results for GV101 (TDI01), a selective ROCK2 inhibitor, in chronic Graft versus Host Disease (cGvHD). The therapy showed best overall response rates at 400 mg and 200 mg at 24 weeks in patients who had failed at least two prior lines of therapy, with the 24-week rate exceeding published 6-month rates for approved steroid-refractory cGvHD therapies.
Why it matters — An MGTX watcher would care because this news reflects progress in the competitive therapeutic landscape for cGvHD treatment by a separate biopharmaceutical company.
MeiraGTx Holdings reported Q2 earnings of $1.71 per share, beating the Zacks Consensus Estimate of a loss of $0.39 per share. This compares to a loss of $0.48 per share in the year-ago quarter.
Why it matters — A MGTX watcher would care because the company significantly exceeded analyst earnings expectations and improved sharply versus the prior-year loss.
MeiraGTx reported second quarter 2026 financial and operational results, announcing FDA Breakthrough Therapy Designation and positive three-year Phase 1 data for AAV2-hAQP1, the completed $25 million acquisition of bota-vec from Johnson & Johnson for XLRP, a $100 million equity financing, and an up to $400 million strategic investment from Oberland Capital. The company stated it anticipates global regulatory filings for bota-vec in 2026 and a potential BLA filing for AAV2-hAQP1 in mid-2027.
Why it matters — The quarter marks key clinical and regulatory progress toward commercialization, with breakthrough designation for AAV2-hAQP1, the finalised bota-vec acquisition, and additional financing to support development of both programmes.
The 8 Wall Street analysts covering MeiraGTx Holdings Plc have a median 12-month price target of $24, with estimates ranging from $16 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering MeiraGTx Holdings Plc, 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MeiraGTx Holdings Plc 79 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, MeiraGTx Holdings Plc ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +147.6% from the last close, and Ticker Nerd's factor model ranks MeiraGTx Holdings Plc 79 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MeiraGTx Holdings Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $50 over the next 12 months.
MeiraGTx Holdings Plc returned +8.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing gene and cell therapies for serious inherited and acquired diseases. MeiraGTx Holdings plc uses a vertically integrated model that combines discovery, development, and manufacturing capabilities to support its genetic medicine programs.
The most recent item we track (GlobeNewsWire, 27 Oct 2026): "MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting". MeiraGTx announced four posters for the ESGCT 2026 Annual Congress and the NEALS Annual Meeting, highlighting its genetic medicine and cell therapy platforms.
MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing gene and cell therapies for serious inherited and acquired diseases. MeiraGTx Holdings plc uses a vertically integrated model that combines discovery, development, and manufacturing capabilities to support its genetic medicine programs. Its current pipeline targets conditions in the eye, salivary gland, and central nervous system, including retinal disorders, radiation-induced xerostomia, and Parkinson’s disease. The company’s work centers on local delivery of small doses designed to produce disease-modifying effects in areas of high unmet medical need. MeiraGTx Holdings plc operates as part of the biotechnology and health technology market, where it contributes to the advancement of precision therapies built around genetic intervention.
CEO Dr. Alexandria Forbes Ph.D. · 393 employees · United States · https://www.meiragtx.com
